Importance of Risk Reduction in COPD
The Report, entitled ‘The Shifting Paradigm in Chronic Obstructive Pulmonary Disease (COPD) Management,’ was initiated and developed by Takeda Pharmaceuticals International GmbH and is a compilation of opinion articles from a panel of key international respiratory experts, the European Federation of Allergy and Airways Diseases Patients’ Association (EFA) and COPD patients, reflecting updated guidance and research. The new expert Report was developed in response to a recent shift in emphasis in COPD management which now places future risk at equal importance to treatment of current disability. Treatment objectives are now divided into two groups: reducing symptoms and reducing risk.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56582-expert-report-on-copd-launch
- TAGS:
- takeda,
- obstructive,
- respiratory,
- disease,
- pharmaceuticals,
- management,
- copd,
- chronic,
- pulmonary,
- health
What do you think of this story?
iReport welcomes a lively discussion, so comments on iReports are not pre-screened before they post. See the iReport community guidelines for details about content that is not welcome on iReport.


Comments